Last reviewed · How we verify
dalteparin injection
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against clotting factors Xa and IIa.
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against clotting factors Xa and IIa. Used for Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip replacement surgery, Treatment of acute deep vein thrombosis and pulmonary embolism, Prophylaxis of ischemic complications in patients with unstable angina and non-Q-wave myocardial infarction.
At a glance
| Generic name | dalteparin injection |
|---|---|
| Also known as | Fragmin, Fragmin® is a registered trademark of Pfizer Health AB, brand name is fragmin, Active comparator, DAL |
| Sponsor | University of Rochester |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (Factor Xa and Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of factor Xa (more potently) and factor IIa (thrombin) in the coagulation cascade. This prevents thrombus formation and propagation. Low-molecular-weight heparins like dalteparin have more predictable pharmacokinetics and longer half-lives than unfractionated heparin, allowing for subcutaneous dosing.
Approved indications
- Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery or hip replacement surgery
- Treatment of acute deep vein thrombosis and pulmonary embolism
- Prophylaxis of ischemic complications in patients with unstable angina and non-Q-wave myocardial infarction
- Extended prophylaxis of venous thromboembolism in patients with cancer
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Injection site pain
- Elevated liver enzymes
- Osteoporosis (with long-term use)
Key clinical trials
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (NA)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis (NA)
- Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients (NA)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Delivery and Implementation of a Randomised Crossover Trial on Thrombosis (NA)
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dalteparin injection CI brief — competitive landscape report
- dalteparin injection updates RSS · CI watch RSS
- University of Rochester portfolio CI